Shotgun metagenomics clinical reporting market seen reaching $3.4B by 2030

The global shotgun metagenomics clinical reporting market is projected to grow from $1.83 billion in 2026 to $3.4 billion by 2030, driven by infectious disease demand, sequencing advances and AI tools. North America led in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Shotgun metagenomics clinical reporting gives clinicians a broader way to identify pathogens and antimicrobial resistance markers from one clinical sample. - The market’s projected expansion signals rising demand for faster infectious disease diagnostics and more precise treatment decisions. - The segment is also tied to broader adoption of precision medicine, decentralized testing and cloud-based bioinformatics.

What happened: - The Business Research Company published its Shotgun Metagenomics Clinical Reporting Global Market Report 2026. - The report says the market will grow from $1.58 billion in 2025 to $1.83 billion in 2026. - The report forecasts the market will reach $3.4 billion by 2030. - The projected CAGR for 2026-2030 is 16.7%. - The historical CAGR cited for the 2025-2026 period is 16.4%. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Shotgun metagenomics clinical reporting uses next-generation sequencing to analyze all genetic material in a clinical sample. - The method can detect bacteria, viruses, fungi and parasites without targeting a single organism first. - Bioinformatics tools interpret sequencing results and help identify infectious agents and antimicrobial resistance markers. - Growth has been supported by advances in next-generation sequencing, more infectious disease outbreaks, higher funding for microbiology and clinical genomics research, expanded hospital molecular testing infrastructure, and greater awareness of antimicrobial resistance monitoring. - The forecast period is expected to benefit from wider use of precision medicine and personalized diagnostics. - Artificial intelligence is expected to play a bigger role in genomic data analysis. - Decentralized and point-of-care sequencing platforms are expected to expand. - Demand is rising for rapid pathogen identification in critical care settings. - Cloud-based bioinformatics tools are expected to streamline clinical workflows. - The report highlights AI-driven pathogen detection with automated clinical interpretation, cloud-enabled real-time genomic data sharing, ultra-fast point-of-care sequencing, genomic analytics for antimicrobial resistance prediction, and hospital-based rapid metagenomic testing. - The report says increased infectious disease prevalence remains one of the main growth drivers. - The World Health Organization reported in October 2024 that 8.2 million people were newly diagnosed with tuberculosis in 2023, up from 7.5 million in 2022. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report update includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables. - A free sample and the full report are available through the company’s website: Download a free sample and View the full report.

Between the lines: - The forecast points to a diagnostic market moving from niche genomic analysis toward broader clinical deployment. - The combination of AI, cloud workflows and point-of-care sequencing suggests the competitive edge will depend on speed, automation and integration with hospital systems. - The tuberculosis data underscores why broad pathogen detection tools are gaining relevance as infectious disease burdens remain high.

What's next: - The market is expected to keep scaling as sequencing gets faster and easier to deploy in clinical settings. - Adoption could accelerate if point-of-care platforms and AI interpretation tools reduce turnaround times and workflow complexity. - Regional growth is likely to be led by Asia-Pacific as hospitals and labs expand molecular testing capacity.

The bottom line: - Shotgun metagenomics clinical reporting is moving toward mainstream diagnostic use, and the market outlook reflects growing demand for rapid, comprehensive infectious disease testing.